Morepen Laboratories has announced a bold expansion strategy aimed at significantly increasing its reach within India’s domestic pharmaceutical market. The company plans to hire over 1,000 medical representatives over the next three years, with 200 of these positions expected to be filled during FY26.
This move marks a substantial step toward scaling its formulations business, which currently stands at approximately ₹325 crore. Morepen aims to triple this figure to ₹1,000 crore in the next five years by deepening its engagement with doctors, pharmacies, and patients across urban and rural India.
“This expansion represents a pivotal moment in Morepen’s journey as we sharpen our focus on the expanding domestic finished dosage market,” said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. He emphasized that this initiative aligns with India’s vision of accessible healthcare for all and aims to deliver stronger margins and improved stakeholder returns.
India’s pharmaceutical market is projected to touch $130 billion by 2030, growing annually at 8.2%. Morepen’s domestic growth will be supported by cost-effective production of new products and enhanced penetration.
The expansion builds on the company’s established leadership in Active Pharmaceutical Ingredients (APIs), where it is the top Indian exporter of six products including Loratadine, Montelukast, and Atorvastatin.
Additionally, Morepen has a strong presence in diagnostics, having installed over 12.33 million glucometers and sold nearly 1.65 billion glucose strips.
The company views this expansion not only as a business growth initiative but also as a reaffirmation of its role in India’s evolving healthcare ecosystem.
